- VBI Vaccines (NASDAQ:VBIV) announces positive results from preclinical studies against several COVID-19 variants of concern as well as the initiation of dosing in the Phase 1b portion of clinical study of VBI’s SARS-CoV-2 vaccine candidates.
- VBI-2905 induced robust neutralizing and antibody binding activity, as a 2-dose course and as a single booster dose, against COVID-19 and variants of concern including Beta and Delta.
- Data also demonstrate trivalent VBI-2901 induced robust and consistent levels of immunity against the ancestral COVID-19 strain and a panel of variants including Beta, Delta, Kappa, and Lambda.
- Also, the first subject has been dosed in Phase 1b portion of ongoing study to assess VBI-2905 as a 1-dose booster in individuals previously immunized with an mRNA vaccine, and a primary 2-dose series in unvaccinated individuals.
- The study is expected to enroll approx. 80 adults, age 18-54, in Canada and Mexico across three study arms.
- VBIV shares fell around 10% in the month during which the filed public offering of up to $125M of common shares.